The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant.

The recent serious challenges in patient management resulting from the COVID-19 pandemic have emphasised the need to optimise therapy for immunosuppressed patients. HCL- SB V, sb a provisional entity in the latest WHO classification, accounts for 10-20% of HCL patients and 0-5% of B-cell chronic lymphoid malignancies, and corresponds to approximately 60-75 new HCL- SB V sb patients each year in the United States. Keywords: guidelines; diagnosis; hairy cell leukaemia EN guidelines diagnosis hairy cell leukaemia 11 14 4 04/01/21 20210401 NES 210401 A European viewpoint (Xavier Troussard) The British Society for Haematology presents very useful and instructive guidelines for the diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL- SB V sb ).1 HCL-like disorders are well-defined entities although overlaps exist between HCL, variant forms of HCL (HCL- SB V sb ), splenic diffuse red pulp lymphoma (SDRPL) and splenic marginal zone lymphoma (SMZL). In newly diagnosed patients, PNAs remain the treatment of choice, but relapses occur in some patients. [Extracted from the article]